This multicenter , open-label , comparator-controlled , phase III study randomly assigned healthy infants 2-to-1 as follows : group 1 received DTaP5-IPV-Hib-HepB , PCV13 , and RV5 at 2 , 4 , and 6 months of age followed by DTaP5 , Hib-OMP , and PCV13 at 15 months of age ; group 2 received DTaP5-IPV/Hib , PCV13 , and RV5 at 2 , 4 , and 6 months of age , with HepB at 2 and 6 months of age , followed by DTaP5 , Hib-TT , and PCV13 at 15 months of age .